Rigshospitalet
Department of Radiation Biology

Benedikte Hasselbalch, MD, Ph.D

Title: Associated Research Assistant, MD, Ph.D
Email: benedikte.hasselbalch@regionh.dk
or doktordikte@gmail.com
Phone: (+45) 35 45 63 29
Fax: (+45) 35 45 63 01

Born:

September 27th, 1974

Current Position:

Associated Research Assistant

Education:
2010PhD
2002Medical Doctor
1995-2002Medical student, University of Odense, Denmark
1990-1993High school, Hjoerring Gymnasium
 
Research and Professional Experiences:
2012Second year resident, Oncology, The Finsencenter, Copenhagen University Hospital
2011Maternity leave
2010First year resident, Oncology, Roskilde Hospital
2010
 
Associated research assistant at Department of Radiation Biology, The Finsencenter, Copenhagen University Hospital
2010PhD thesis defended and accepted, Copenhagen University
2006-2009Ph.D student at Department of Radiation Biology, The Finsencenter, Copenhagen University Hospital
2005 Research assistant, Department of Radiation Biology, The Finsencenter, Copenhagen University Hospital
2004-2006M.D., Department of Oncology, The Finsencenter, Copenhagen University Hospital
2004M.D., Faaborg Hospital
2002-2004Residency in Fyens county, Denmark
 
Grants and Scholarships:
 2009 The Young Investigator Award, at the Scandinavian Neuro-Oncology Society Meeting, Helsinfors, Finland
2009Awarded a research grant from Læge Agnethe Løvgreens legat
2008Awarded a travel grant from the Danish Cancer Society
2007Awarded a travel grant from the Danish Cancer Society
2005Awarded a travel grant from the Danish Cancer Society
2005Awarded a scholarship from American Association for Cancer Research, attending a workshop in cancer research
 
Conferences and Meetings:
Oral presentation 
2008B. Hasselbalch. “In Vitro Effects of cetuximab on EGFR & Downstream mediators with a focus on gliomas”. At Dansk Selskab for Klinisk Onkologi (DSKO) Annual Meeting, Vejle, Denmark
2007B. Hasselbalch. “Bevacizumab, a monoclonal antibody to the Vascular Endothelial Growth Factor (VEGF) and Irinotecan for treatment of recurrent primary malignant brain tumors in adults” and B. Hasselbalch. “In Vitro Effects of cetuximab on EGFR & Downstream mediators”. at the Scandinavian Neuro-Oncology Society Meeting, Copenhagen, Denmark
2005SKA, post-ASCO meeting, Copenhagen
 
Poster presentation
2009B. Hasselbalch, U. Lassen, M.T. Stockhausen, I.J. Christensen, J.G. Eriksen, H. Broholm, M. Holmberg, S. Hansen, M. Sørensen, K. Grunnet, H. S. Poulsen. “Immunohistochemical evaluation of high-grade glioma patients treated with bevacizumab and irinotecan, with or without cetuximab”. Society for Neuro-Oncology’s 14th Annual Scientific Meeting, New Orleans, LA, USA
2009B. Hasselbalch, U. Lassen, M.T. Stockhausen, I.J. Christensen, J.G. Eriksen, H. Broholm, M. Holmberg, S. Hansen, M. Sørensen, K. Grunnet, H. S. Poulsen. “Immunohistochemical evaluation of high-grade glioma patients treated with bevacizumab and irinotecan, with or without cetuximab”. The Scandinavian Neuro-Oncology Society Meeting, Helsingfors, Finland
2008B. Hasselbalch, U. Lassen, M. Sørensen, S. Hansen, M. Holmberg, M. Kosteljanetz, H.
Broholm, HS. Poulsen “A phase II trial with cetuximab, bevacizumab and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolomide”. The Society for Neuro-Oncology’s 13th Annual Scientific Meeting, Las Vegas, NV, USA
2008B. Hasselbalch, U. Lassen, M. Sørensen, S. Hansen, M. Holmberg, M. Kosteljanetz, H.
Broholm, HS. Poulsen “A phase II trial with cetuximab, bevacizumab and irinotecan for patients with primary glioblastomas and progression after radiation therapy and temozolomide”. The 21th Annual Meeting of the Danish Association for Cancer Research, Charlottenlund
2007B. Hasselbalch, U. Lassen, K. Grunnet, M. Kosteljanetz, H Laursen, H.S Poulsen. “Bevacizumab, a monoclonal antibody to the Vascular Endothelial Growth Factor (VEGF), and Irinotecan for treatment of recurrent primary malignant brain tumors in adults” and B. Hasselbalch, M.T. Stockhausen, U. Lassen. H.S. Poulsen. “In Vitro Effects of cetuximab on EGFR and Down Stream Mediators, with a focus on gliomas”. Society for Neuro-Oncology’s 12th Annual Scientific Meeting, Dallas, TX, USA2007
2007B. Hasselbalch, M.T. Stockhausen, U. Lassen, H.S. Poulsen. “In Vitro Effects of cetuximab on EGFR and Down Stream Mediators, with a focus on gliomas”. The 20th Annual Meeting of the Danish Association for Cancer Research, Charlottenlund, Denmark
 
Teaching experience:
2010Lecture at Foreningen for Yngre Onkologer’s efterårskursus: “Vækstsignal blokerende behandlinger i onkologien

 

Publications with peer-review:
1.Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol. Oct 2009; 48(1): 52-58.
2.Sørensen M, Gaziel TB, Hasselbalch B, Poulsen HS, Lassen U. Severe Skin Lesions in Patients with Glioblastoma Multiforme Treated with a Combination of Cetuximab, Bevacizumab, and Irinotecan. European Journal of Clinical and Medical Oncology 2009;1(2):73-75.
3.Hasselbalch B, Lassen U., Hansen S., Holmberg M., Sørensen M., Kosteljanetz, M., Broholm H., Stockhausen MT., Poulsen HS. Cetuximab, Bevacizumab and Irinotecan for Patients With Primary Glioblastoma and Progression After Radiation Therapy and Temozolomide: A Phase II Trial. Neuro-Oncol. 2010 May;12(5):508-516.
4.Hasselbalch B, Eriksen JG, Broholm H, Christensen IJ, Grunnet K, Horsman MR, Poulsen HS, Stockhausen MT, Lassen U. Prospective evaluation of angiogenic, hypoxic and EGFR related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS. 2010 Aug;118(8):585-94
5.Hasselbalch B, Lassen U, Poulsen HS and Stockhausen MT. Cetuximab insuffiently inhibits glioma cell growth due to persistent EGFR downstream signalling. Cancer Invest. 2010 Oct;28(8):775-87.
6.Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS: Irinotecan and bevacizumab treatment of recurrence of Glioblastoma Multiforme. Expert Opin Pharmacother. 2011 Apr;12(5):825-33.
7.Lassen U, Sørensen M, Gaziel, TB, Hasselbalch B, Poulsen HS: Phase II study of bevacizumab and Temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Research. In press
 

.

Publications without peer-review:
Book Chapters
1.Hasselbalch B, Lassen U, Poulsen HS.Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan. In “TUMORS OF THE CENTRAL NERVOUS SYSTEM” edited by M.A. Hayat. Published 2011 by Springer
 

 

 

 

The Finsencenter, Section 6321, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark